Citigroup Downgrades Juno Therapeutics (JUNO) to Neutral

Juno Therapeutics (NASDAQ:JUNO) was downgraded by stock analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Wednesday.

Several other equities analysts also recently issued reports on JUNO. Morgan Stanley reissued an “equal weight” rating and set a $43.00 price target (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a report on Friday, October 6th. Maxim Group reissued a “buy” rating and set a $56.00 price target (up from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Cowen reissued a “buy” rating and set a $49.00 price target on shares of Juno Therapeutics in a report on Friday, October 27th. Finally, SunTrust Banks raised shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $47.26.

Juno Therapeutics (JUNO) opened at $71.37 on Wednesday. The company has a market cap of $8,150.00, a PE ratio of -21.05 and a beta of 2.32. Juno Therapeutics has a 1-year low of $19.07 and a 1-year high of $74.35. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the firm earned ($0.57) EPS. The firm’s revenue for the quarter was up 115.4% compared to the same quarter last year. research analysts anticipate that Juno Therapeutics will post -4.02 earnings per share for the current fiscal year.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.76, for a total value of $391,650.00. Following the completion of the sale, the chief financial officer now owns 772,082 shares in the company, valued at approximately $34,558,390.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Hans Edgar Bishop sold 270,250 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total transaction of $12,477,442.50. Following the completion of the sale, the chief executive officer now owns 2,772,679 shares of the company’s stock, valued at approximately $128,014,589.43. The disclosure for this sale can be found here. Insiders sold a total of 336,206 shares of company stock valued at $15,541,821 in the last 90 days. Corporate insiders own 15.08% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in shares of Juno Therapeutics by 64.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 17,684 shares of the biopharmaceutical company’s stock worth $528,000 after buying an additional 6,943 shares during the period. Bank of New York Mellon Corp grew its position in shares of Juno Therapeutics by 7.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after buying an additional 19,057 shares during the period. JPMorgan Chase & Co. grew its position in shares of Juno Therapeutics by 80.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 113,124 shares of the biopharmaceutical company’s stock worth $3,382,000 after buying an additional 50,378 shares during the period. Teachers Advisors LLC grew its position in shares of Juno Therapeutics by 15.4% during the 2nd quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after buying an additional 9,890 shares during the period. Finally, TIAA CREF Investment Management LLC grew its position in shares of Juno Therapeutics by 9.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 188,481 shares of the biopharmaceutical company’s stock worth $5,634,000 after buying an additional 15,491 shares during the period. Hedge funds and other institutional investors own 69.94% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://stocknewstimes.com/2018/01/19/citigroup-downgrades-juno-therapeutics-juno-to-neutral.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply